MannKind Corporation 10-Q Summary
Business Context and Reporting Period
MannKind is a biopharmaceutical company commercializing Afrezza inhaled insulin and the V-Go wearable insulin delivery device, while manufacturing Tyvaso DPI for United Therapeutics (UT). The filing covers the three and nine months ended September 30, 2023, compared with the same periods in 2022.
Tyvaso DPI royalties and manufacturing revenue from UT were significant contributors to results. As of September 30, 2023, MannKind had 269.5 million common shares outstanding and an accumulated deficit of $3.2 billion.
Financial Performance and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $51.3 million | $32.8 million | $140.5 million | $63.7 million |
| Commercial product sales | $17.9 million | $16.3 million | $53.8 million | $38.8 million |
| Collaboration and services revenue | $13.1 million | $10.3 million | $35.7 million | $18.4 million |
| Royalty revenue | $20.2 million | $6.2 million | $51.0 million | $6.5 million |
| Net income (loss) | $1.7 million | $(14.4) million | $(13.3) million | $(69.5) million |
| Basic EPS | $0.01 | $(0.06) | $(0.05) | $(0.27) |
| Cash flow from operations | Not separately provided | Not separately provided | $12.4 million | $(78.3) million |
- Q3 revenue increased 56%, while nine-month revenue increased 121%, primarily because of higher Tyvaso DPI royalties, increased UT manufacturing activity, higher Afrezza sales and the inclusion of V-Go for a full nine months.
- Commercial product gross margin improved to 78% in Q3 and 73% for the nine-month period, versus 69% in each comparable 2022 period.
- Q3 operating income was $5.1 million, compared with an operating loss of $9.6 million in Q3 2022. Nine-month operating income was $0.8 million, compared with an operating loss of $51.3 million.
- Research and development expense increased 142% in Q3 and 75% year to date, driven by MNKD-101, the INHALE-3 Afrezza post-marketing study, increased headcount and other pipeline activities.
- Q3 operating margin was approximately 10%; the nine-month operating margin was approximately 1%. Net income remained affected by interest expense and financing-related costs.
Liquidity, Capital Expenditures and Debt
- At September 30, 2023, cash and cash equivalents were $83.0 million, short-term investments were $58.0 million and long-term investments were $3.3 million, for total cash and investments of approximately $144.3 million.
- Operating activities generated $12.4 million during the first nine months, supported in part by increased deferred revenue. Investing activities provided $5.9 million, while financing activities used $5.1 million.
- Capital expenditures were $36.6 million year to date, substantially related to the Tyvaso DPI manufacturing facility expansion and expected to be reimbursed by UT.
- Total debt had a net carrying value of $273.2 million and principal outstanding of approximately $277.1 million. Principal maturities include $20.0 million in 2024, $22.2 million in 2025 and $230.0 million of senior convertible notes due in 2026.
- Debt includes $230.0 million of 2.50% senior convertible notes due March 2026, $38.3 million under the MidCap facility due August 2025 and an $8.8 million Mann Group convertible note due December 2025.
- The MidCap facility requires monthly principal payments beginning September 2023 and includes an Afrezza revenue covenant when unrestricted cash and short-term investments are below $90.0 million. The company reported compliance as of September 30, 2023.
- Management stated that available resources, expected product sales, royalties and manufacturing revenue should fund operations for at least the next twelve months, but acknowledged that additional financing may be required for longer-term needs.
Material Changes Versus the Prior Comparable Period
- Tyvaso DPI royalties increased to $20.2 million in Q3 and $51.0 million year to date, versus $6.2 million and $6.5 million, respectively, in the prior-year periods, reflecting higher patient demand.
- Afrezza net revenue increased approximately 24% in Q3 and 26% year to date, primarily from higher demand and pricing. The gross-to-net adjustment remained substantial at approximately 38% of Afrezza gross revenue.
- V-Go net revenue increased 92% year to date because 2023 included nine months of ownership versus four months in the 2022 period. Q3 V-Go net revenue declined 18%, reflecting lower demand and higher rebates.
- Deferred revenue increased to $73.1 million at September 30, 2023 from $39.4 million at December 31, 2022, primarily related to UT-funded manufacturing facility capital improvements.
- Property and equipment, net increased to $80.4 million from $45.1 million, primarily reflecting manufacturing expansion.
- Stockholders’ deficit was $251.8 million, compared with $250.5 million at year-end 2022. The company issued approximately 1.5 million shares through its at-the-market program for $6.9 million of gross proceeds.
- The company increased its authorized common shares from 400 million to 800 million and added 25 million shares to its equity incentive plan during 2023.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide formal revenue, earnings or margin guidance. Management expects continued investment in manufacturing, commercialization and pipeline development and expects operating results to fluctuate.
- Management identified Tyvaso DPI demand, Afrezza and V-Go sales, and manufacturing capacity as important drivers of future performance.
- The planned Phase 2/3 study of MNKD-101 was delayed after a fire at the German contract manufacturer producing the investigational product. Commencement moved from late 2023 to the first half of 2024.
- Research and development activities include MNKD-101 and the INHALE-3 Afrezza post-marketing study. A separate long-term Afrezza safety study requested by the FDA has not commenced and could require substantial capital.
- The company recorded $3.7 million of inventory write-offs during the first nine months and paid a $5.0 million milestone rights payment during Q3. Remaining milestone rights could require payments of up to $55.0 million if specified milestones are achieved.
- Remaining insulin purchase commitments under the Amphastar agreement were approximately €61.1 million through 2027, and the company had recognized purchase-commitment losses of $64.6 million on its balance sheet.
- Key risks include manufacturing concentration, reliance on Amphastar and other suppliers, contract manufacturing of V-Go in China, reimbursement and rebate pressure, regulatory requirements, clinical-development uncertainty, substantial debt and purchase commitments, potential dilution and the need for future capital.
- Legal proceedings were described as ordinary-course matters that management does not believe will have a material adverse effect. No material litigation accrual was recorded.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2023, and reported no material changes to internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify the sustainability of Tyvaso DPI royalty growth and UT manufacturing volumes, including the terms and timing of deferred revenue recognition.
- Assess whether Afrezza demand and pricing can offset high gross-to-net deductions, and monitor V-Go demand and rebate trends.
- Review liquidity against the $277.1 million of debt principal, 2024–2026 maturities, MidCap amortization and the Afrezza revenue covenant.
- Confirm the timing, cost and UT reimbursement of the manufacturing expansion and whether additional capital will be required.
- Track MNKD-101 manufacturing remediation and the anticipated first-half 2024 clinical-trial start, along with the status and cost of the FDA-requested Afrezza safety study.
- Evaluate exposure to insulin purchase commitments, milestone rights, sale-leaseback financing obligations and potential equity dilution from convertible notes and equity programs.